Wells Fargo & Company Dbv Technologies S.A. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Shares
4 transactions
Others Institutions Holding DBVT
# of Institutions
32Shares Held
37.7MCall Options Held
0Put Options Held
0-
Baker Bros. Advisors LP New York, NY14.6MShares$13.6 Million0.14% of portfolio
-
Braidwell LP Stamford, CT7.84MShares$7.29 Million0.19% of portfolio
-
Yiheng Capital Management, L.P. San Francisco, CA5.57MShares$5.18 Million0.23% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.11MShares$2.89 Million0.01% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.71MShares$2.52 Million0.27% of portfolio
About DBV Technologies S.A.
- Ticker DBVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,776,992
- Market Cap $175M
- Description
- DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...